Application Note

Super Short Activated CAR-T Process

GettyImages-1317697250-CAR-T-cell-therapy

The conventional process for generating activated CAR-T cells typically takes seven to nine days, but the Resilience three-day short-cycle process significantly shortens this time, reducing the materials and labor needed for production and enabling faster patient treatment. This accelerated process yields T-cells with high purity and activation levels, as well as a younger phenotype characterized by central memory and naïve cells, which may enhance their persistence.

Additionally, CAR-T cells produced in just three days demonstrate improved biological activity, including higher IFN-γ release and cytotoxicity against target cells, even at lower effector-to-target ratios. Overall, the Resilience three-day process not only cuts turnaround time and production costs but also requires fewer CAR-T cells to achieve effective dosing — approximately two log-fold less than conventional methods.

Learn more about this by downloading the white paper below.

access the Application Note!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Bioprocess Online